Form 4: Kura Oncology Director Mary T. Szela Acquires Options to Purchase 26,000 Shares
SEC Form 4 Filing
Mary T. Szela, a director of Kura Oncology, acquired options to purchase 26,000 shares of common stock on June 5, 2024.
Summary
- On June 5, 2024, Mary T. Szela, a director of Kura Oncology, Inc., acquired options to purchase 26,000 shares of the company's common stock at an exercise price of $21.79.
- The options vest in full on the one-year anniversary of the grant date and expire on June 4, 2034.
- Following this transaction, Ms. Szela directly owns options to purchase 26,000 shares of Kura Oncology's common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports a transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Positives
- A director's acquisition of options may signal confidence in the company's future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, or those holding more than 10% of a company's shares) transact in their company's stock. These filings provide transparency to the market regarding insider activity.
Stakeholder Impact
- The transaction could provide a slight positive signal to shareholders, as it indicates a director is increasing their stake in the company.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of the transaction: Mary T. Szela acquired options to purchase common stock. |
| 06/05/2025 | Vesting date: Options vest in full one year after the grant date. |
| 06/04/2034 | Expiration date: Options expire ten years after the grant date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.